This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Hiroyuki Koshiyama, MD; Toshikiyo Koh, MD; Teuki Sone, MD
Kyoto, Japan

Arch Intern Med. 1994;154(17):1997.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It has been well documented that overt hypothyroidism is associated with hyperlipidemia, and that overt hyperthyroidism causes a decrease in bone mineral density. However, it has recently been debated whether subclinical hypothyroidism is associated with an increase in total cholesterol^1,2 and whether subclinical hyperthyroidism causes a decrease in bone mineral density.^3-5 These controversies raise the therapeutic dilemma about levothyroxine (l-T4) replacement therapy in patients with hypothyroidism. We investigated the total cholesterol and bone mineral density levels in patients with hypothyroidism who were treated with l-T4 replacement. These levels and the thyroid stimulating hormone level were examined in a total of 200 patients with hypothyroidism. The thyroid stimulating hormone levels were measured using an immunoradiometric assay (TSH-RIABEAD II, Dinabot Co, Tokyo, Japan). The subjects included those who were diagnosed as having Hashimoto's thyroiditis (n=191), postoperative hypothyroidism (n=5) (benign tumor [n=1] and malignant tumor [n=4]), and Graves' disease after therapy . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?